|
Market Cap (25-Jun) $4,172,944 (725th) |
Close (30-Jun) $0.260 |
Volume (30-Jun) 239,872 |
Shortsold (5-Oct) 64,772 (0.03%) (542nd) |
|
52w High $0.035 |
52w Low $0.012 |
P/E 11.29 |
EPS -0.06 |
UBI released this announcement to the ASX on 6 February 2023, 8:58. The announcement is marked as price sensitive, and is 2 page(s) in length and 135.46kb in size.
You can view all announcements from UBI and see how they appear on a price chart on the announcements page.
At the date of this announcement, UBI was 0.029% short sold according to ASIC data. It was ranked the 538th most shorted stock on the ASX. It remains ranked 542nd as of the latest reported data (05 October 2023).
| Other Recent Announcements from UBI | |
|---|---|
| Results of 2023 Annual General meeting | 22 May 2023, 12:14 |
| CEO's AGM address to Securityholders | 22 May 2023, 8:33 |
| Q1 2023 Results | 11 May 2023, 15:41 |
| UBI makes first sales of Xprecia Prime in Europe | 6 February 2023, 8:58 |
| UBI launches new product - Fructose Test for Sentia | 30 January 2023, 8:37 |
| December 2022 Quarterly Activity Report and Appendix 4C | 27 January 2023, 16:13 |
| UBI completes Xprecia Prime clinical trial in USA | 23 January 2023, 10:21 |
You must be logged in to post a reply.
Universal Biosensors, Inc 